Upload
maude-pitts
View
223
Download
1
Tags:
Embed Size (px)
Citation preview
Post-Marketing AE Reports of Post-Marketing AE Reports of Topical Calcineurin InhibitorsTopical Calcineurin InhibitorsPost-Marketing AE Reports of Post-Marketing AE Reports of Topical Calcineurin InhibitorsTopical Calcineurin Inhibitors
Pediatric Advisory Subcommittee of the Anti-Infective Drugs Advisory Committee
Marilyn R. Pitts, Pharm.D.,Marilyn R. Pitts, Pharm.D.,Safety Evaluator, Office of Drug SafetySafety Evaluator, Office of Drug Safety
October 30, 2003October 30, 2003
Pediatric Advisory Subcommittee of the Anti-Infective Drugs Advisory Committee
Marilyn R. Pitts, Pharm.D.,Marilyn R. Pitts, Pharm.D.,Safety Evaluator, Office of Drug SafetySafety Evaluator, Office of Drug Safety
October 30, 2003October 30, 2003
Center for Drug Evaluation and ResearchCenter for Drug Evaluation and Research
2
OutlineOutline
• Background • Drug Use• Methods• AERS Adverse Event Profile
– Pediatric subgroup– Death/Hospitalized cases– Malignant and non-malignant cases – Infection cases
• Summary
• Background • Drug Use• Methods• AERS Adverse Event Profile
– Pediatric subgroup– Death/Hospitalized cases– Malignant and non-malignant cases – Infection cases
• Summary
3
Topical Calcineurin Inhibitors Topical Calcineurin Inhibitors Topical Calcineurin Inhibitors Topical Calcineurin Inhibitors
Pimecrolimus 1%
Tacrolimus 0.03% & 0.1%
Approved: 12/13/2001 12/08/2000
2nd Line Tx: Yes Yes
Indication: Mild to mod. atopic
dermatitis…
Mod. To Severe atopic dermatitis…
Approved for children < 2
No No
4
# Prescriptions & Appearances # Prescriptions & Appearances IMS Health National Prescription Audit IMS Health National Prescription Audit PlusPlusTMTM, ,
IMS National Disease & Therapeutic Index AuditIMS National Disease & Therapeutic Index AuditTMTM
# Prescriptions & Appearances # Prescriptions & Appearances IMS Health National Prescription Audit IMS Health National Prescription Audit PlusPlusTMTM, ,
IMS National Disease & Therapeutic Index AuditIMS National Disease & Therapeutic Index AuditTMTM
Since Approval Pimecrolimus
1%
Topical Tacrolimus
0.03%, 0.1%
Total Rx 3,230,000 2,004,000
Appearances0 to 2 yrs 17% 8%
Appearances3 to 16 yrs 36% 29%
5
Some Common Elements in Some Common Elements in Product LabelingProduct Labeling
Some Common Elements in Some Common Elements in Product LabelingProduct Labeling
Pimecrolimus 1%
Topical Tacrolimus
0.03% + 0.1%
Varicella zoster Yes Yes
Herpes Simplex Yes Yes
Eczema herpeticum Yes Yes
Lymphadenopathy Yes Yes
Local Skin rxn Yes Yes
Systemic Absorption Yes Yes
6
AERS Electronic DatabaseAERS Electronic Database
– Adverse Event Reporting System
• 1969 – SRS
• 1997 – replaced by AERS
• ~ 3 million AE reports for drugs–Medwatch forms
– Adverse Event Reporting System
• 1969 – SRS
• 1997 – replaced by AERS
• ~ 3 million AE reports for drugs–Medwatch forms
7
MethodsMethods
Separate search of AERS database:
– All reports with pimecrolimus as suspect agent
– All reports with tacrolimus administered topically as suspect agent
Separate search of AERS database:
– All reports with pimecrolimus as suspect agent
– All reports with tacrolimus administered topically as suspect agent
Pimecrolimus 1% CreamPimecrolimus 1% CreamPimecrolimus 1% CreamPimecrolimus 1% CreamApproved 12/13/2001Approved 12/13/2001
9
Pimecrolimus – Overall Findings Pimecrolimus – Overall Findings (Adult and Pediatric, n = 79)(Adult and Pediatric, n = 79)
Pimecrolimus – Overall Findings Pimecrolimus – Overall Findings (Adult and Pediatric, n = 79)(Adult and Pediatric, n = 79)
Location: US (64), Foreign (15)
Gender: Female (53), Males (23), NR (3)
Age: < 2 years (14)2 to 16 years (17)
Adverse Events:
60% - labeled90% - involved the skin
Cases of Interest:
Hospitalization (7)Tumor growth (2)Pediatric (32)
10
Demographics of Demographics of Pimecrolimus Pediatric Cases (32) Pimecrolimus Pediatric Cases (32)
Demographics of Demographics of Pimecrolimus Pediatric Cases (32) Pimecrolimus Pediatric Cases (32)
Indications: Atopic or allergic dermatitis (25)
Location: US (23), Foreign (9)
Gender: Male (16), Female (16)
Age: 2 months – 15 years, median = 2 years (n = 30)
< 2 years (14)
AEs Skin reactions predominateNon-malignant tumor (2)Infections (7)
11
Hospitalized Pimecrolimus Hospitalized Pimecrolimus Pediatric Cases (n = 4)Pediatric Cases (n = 4)
Hospitalized Pimecrolimus Hospitalized Pimecrolimus Pediatric Cases (n = 4)Pediatric Cases (n = 4)
Ages: 4 months, 6 months, 9 months and 18 months
18 month old Staph aureus + axillary adenitis. Hosp for drainage, irrigation and IV Abx.
9 month old Osteomyelitis, osteitis & soft tissue infection 20 days after starting pimecrolimus.
12
Pimecrolimus Associated Pimecrolimus Associated Pediatric Infection Cases (7)Pediatric Infection Cases (7)Pimecrolimus Associated Pimecrolimus Associated
Pediatric Infection Cases (7)Pediatric Infection Cases (7)
Location: US (4), foreign (3)
Age Range: 9 months to 15 years, median = 18 months (n = 7)
Outcome: Hospitalization (2)Other (2)
Infections Seen:
Abscess, Bronchitis, Eczema herpeticum + infected eyes, Scarlatina, Soft tissue infection, Staph aureus + adenitis, Strep throat
13
Non-Malignant Tumor Growth Non-Malignant Tumor Growth Pimecrolimus Pediatric Cases (2)Pimecrolimus Pediatric Cases (2)
Non-Malignant Tumor Growth Non-Malignant Tumor Growth Pimecrolimus Pediatric Cases (2)Pimecrolimus Pediatric Cases (2)
Onset Type
5 year old 49 days Granulomatous lymphadenitis w/ reactive hyperplasia
Unknown age NR Facial tumor
Topical Tacrolimus OintmentTopical Tacrolimus Ointment0.03%, 0.1%0.03%, 0.1%
Topical Tacrolimus OintmentTopical Tacrolimus Ointment0.03%, 0.1%0.03%, 0.1%Approved 12/08/2000Approved 12/08/2000
15
Topical Tacrolimus – Overall Topical Tacrolimus – Overall Findings (Adult and Pediatric, n = 183)Findings (Adult and Pediatric, n = 183)
Topical Tacrolimus – Overall Topical Tacrolimus – Overall Findings (Adult and Pediatric, n = 183)Findings (Adult and Pediatric, n = 183)
Location: US (164), Foreign (19)
Gender: Female (103), Male (74), NR (6)
Age: < 2 years (7)2 to 16 years (29)
Adverse Events:
95% - labeled50% - involved the skin
Cases of Interest:
Death (3), Hosp (18)Pediatric (36)Malignancy (5)Acute Renal Failure (4)
16
Topical Tacrolimus Topical Tacrolimus Death Cases (3)Death Cases (3)
Topical Tacrolimus Topical Tacrolimus Death Cases (3)Death Cases (3)
Onset Adverse Event
28 year old
1 months Kaposi’s sarcoma
54 year old
3 months Non-Hodgkin’s lymphoma
3 year old 9 months Streptococcal pneumonia, sepsis
17
Demographics of Demographics of Topical Tacrolimus Pediatric Topical Tacrolimus Pediatric
Cases (36) Cases (36)
Demographics of Demographics of Topical Tacrolimus Pediatric Topical Tacrolimus Pediatric
Cases (36) Cases (36)
Indication: Atopic dermatitis
Location: US (35), Foreign (1)
Gender: Male (18), Female (13), NR (5)
Age: < 2 yrs (7)2 to 16 (29)
Product: 0.03% (21), 0.1% (10), NR (5)
AEs Skin and application site rxn predominatedInfections (10)Serum levels (2)
18
Topical Tacrolimus Topical Tacrolimus Associated Pediatric Infection Associated Pediatric Infection
Cases (10)Cases (10)
Topical Tacrolimus Topical Tacrolimus Associated Pediatric Infection Associated Pediatric Infection
Cases (10)Cases (10)
Location: US (9), foreign (1)
Age Range: 13 months to 16 years, median = 4 years (n = 10)
Outcome: Death (1), Hospitalization (3)Other (6)
Infections Seen:
Pneumonia/sepsis, eczema herpeticum, staph aureus sepsis, chickenpox, warts, strep sepsis, herpes zoster, herpes simplex keratitis, erythema infectiosum
19
Malignancies Associated Malignancies Associated with Topical Tacrolimus (5)with Topical Tacrolimus (5)Malignancies Associated Malignancies Associated
with Topical Tacrolimus (5)with Topical Tacrolimus (5)
Location: US (4), foreign (1)
Age Range: 28 to 56 years, median = 52 years (n = 5)
Outcome: Death (2)Other (3)
Onset: 1 month to 6 months (median = 3.5)
Malignancies Seen:
Anaplastic large cell lymphoma w/mets, B cell lymphoma, Kaposi's sarcoma, non-Hodgkin's lymphoma
20
Overall Summary Pimecrolimus & Topical Tacrolimus
Overall Summary Pimecrolimus & Topical Tacrolimus
• AERS Post-Marketing AE Reports
– Serious Outcomes
– Malignancies
– Infections
– Pediatric AE Reports • off label use in children < 2 years old
(pimecrolimus, topical tacrolimus)• adult topical tacrolimus product use in
children
• AERS Post-Marketing AE Reports
– Serious Outcomes
– Malignancies
– Infections
– Pediatric AE Reports • off label use in children < 2 years old
(pimecrolimus, topical tacrolimus)• adult topical tacrolimus product use in
children
21
AcknowledgementsAcknowledgementsMark Avigan, M.D., C.M., Acting Director, DDRE,
Office of Drug Safety
Renan Bonnel, Pharm.D., M.Ph., Safety Evaluator, DDRE, Office of Drug Safety
Claudia B. Karwoski, Pharm.D., Team Leader, DDRE, Office of Drug Safety
Division of Dermatological and Dental Drug Products
Office of Counter-Terrorism and Pediatric Drug Development
Mark Avigan, M.D., C.M., Acting Director, DDRE, Office of Drug Safety
Renan Bonnel, Pharm.D., M.Ph., Safety Evaluator, DDRE, Office of Drug Safety
Claudia B. Karwoski, Pharm.D., Team Leader, DDRE, Office of Drug Safety
Division of Dermatological and Dental Drug Products
Office of Counter-Terrorism and Pediatric Drug Development